Erastin: Benchmark Ferroptosis Inducer for Cancer Biology & Oxidative Stress Research

Executive Summary: Erastin (CAS 571203-78-6) is a small molecule that reliably induces ferroptosis, a form of regulated, iron-dependent, non-apoptotic cell death, in a variety of cancer models (Liu et al., 2022). It acts by inhibiting the cystine/glutamate antiporter system Xc⁻, resulting in intracellular glutathione depletion and elevated reactive oxygen species (ROS) (APExBIO). Erastin is highly selective for tumor cells with oncogenic RAS (HRAS, KRAS) or BRAF mutations, making it a key tool in targeted cancer research. Its solid form (molecular weight 547.04, formula C30H31ClN4O4) is insoluble in water and ethanol but dissolves in DMSO at ≥10.92 mg/mL with gentle warming. Recent studies confirm its benchmark status for oxidative stress and ferroptosis assays, especially in engineered cell lines and HT-1080 fibrosarcoma cells (Liu et al., 2022).

Biological Rationale

Ferroptosis is a regulated cell death pathway distinct from apoptosis and necrosis. It is characterized by iron-dependent lipid peroxidation and depletion of glutathione. The cystine/glutamate antiporter system Xc⁻ imports cystine, a precursor for glutathione synthesis, thereby maintaining cellular redox balance (Liu et al., 2022). Tumor cells with mutations in RAS or BRAF oncogenes exhibit increased susceptibility to ferroptosis, likely due to altered redox homeostasis. Erastin exploits this vulnerability by disrupting cystine uptake, tipping the balance toward lethal oxidative stress. Ferroptosis is implicated in cancer, neurodegeneration, and ischemic injury. Targeting ferroptosis provides a strategy for selectively eliminating cancer cells refractory to apoptosis (related overview; this article details updated mechanistic insights and experimental parameters).

Mechanism of Action of Erastin

Erastin modulates voltage-dependent anion channels (VDACs) on the mitochondrial membrane, altering metabolite flux and facilitating ROS accumulation. Its primary action is inhibition of the system Xc⁻ antiporter (SLC7A11/xCT), which exchanges extracellular cystine for intracellular glutamate. This inhibition leads to rapid cystine depletion, impaired glutathione synthesis, and accumulation of lipid peroxides. The resulting oxidative stress is iron-dependent and caspase-independent, defining the ferroptotic phenotype. In RAS- or BRAF-mutant tumor cells, these effects are amplified by oncogenic signaling, enhancing sensitivity. Erastin does not activate classical apoptotic markers (e.g., caspase-3 cleavage) under typical assay conditions (APExBIO).

Evidence & Benchmarks

• Erastin (1 μM) induces ferroptosis in HT-1080 fibrosarcoma cells within 24 hours, marked by increased lipid ROS and cell death (Liu et al., 2022, DOI).
• Inhibiting system Xc⁻ with Erastin leads to glutathione depletion and iron-dependent, non-apoptotic cell death in neuronal HT22 cells (Liu et al., 2022, DOI).
• Erastin’s effects are potentiated in tumor cell lines with HRAS or KRAS mutations, showing selective cytotoxicity in engineered models (Dixon et al. 2012, DOI).
• Myriocin, an inhibitor of sphingolipid synthesis, protects against Erastin-induced ferroptosis by stabilizing HIF1a and activating the HIF-1 pathway (Liu et al., 2022, DOI).
• Erastin is insoluble in water/ethanol but dissolves in DMSO at ≥10.92 mg/mL with warming; solutions are unstable for long-term storage (APExBIO).

For further mechanistic guidance, see Erastin and the Ferroptosis Frontier, which offers translational perspectives. This article provides updated, peer-reviewed evidence on Erastin’s interaction with metabolic and redox pathways.

Applications, Limits & Misconceptions

Erastin is widely used for:

• Ferroptosis induction in RAS/BRAF-mutant tumor cell models.
• Assays of oxidative stress, redox regulation, and iron-dependent cell death.
• Screening of neuroprotective or ferroptosis-modulating compounds in vitro.
• Mechanistic studies of caspase-independent cell death pathways.

It is not effective in cell types lacking system Xc⁻ expression or in the absence of iron. Erastin does not induce apoptosis or necrosis under standard conditions. Its activity can be blocked by ferroptosis inhibitors (e.g., ferrostatin-1) but not by caspase inhibitors. For exploration of Erastin's non-cancer applications, see Erastin: Uncovering Ferroptosis Beyond Cancer; this article provides updated boundaries and mechanistic limits.

Common Pitfalls or Misconceptions

• Erastin does not induce ferroptosis in the absence of iron; iron chelators abrogate its effect.
• It is ineffective in cells lacking functional system Xc⁻ (e.g., certain primary neuronal types).
• Solutions in DMSO degrade over time; always prepare fresh aliquots for each experiment.
• Erastin does not activate classical apoptotic or necrotic cell death markers.
• Cellular context—particularly RAS/BRAF status—strongly determines sensitivity.

Workflow Integration & Parameters

APExBIO recommends using Erastin (B1524) at 10 μM for 24 hours to induce robust ferroptosis in HT-1080 or RAS/BRAF-mutant tumor cells. Stock solutions can be prepared in DMSO at ≥10.92 mg/mL with gentle warming, then diluted in culture media immediately before use. Erastin is not stable in solution for long-term storage; freeze-dried powder should be kept at -20°C. Positive controls may include treatment with known ferroptosis inhibitors (e.g., ferrostatin-1) to confirm specificity. Readouts include cell viability assays, lipid ROS detection, and glutathione quantification. For scenario-driven integration in advanced models, see Erastin (SKU B1524): Reliable Ferroptosis Induction for Cancer Biology; this article provides additional troubleshooting guidance and scenario contrasts.

Conclusion & Outlook

Erastin remains a gold-standard ferroptosis inducer for research in cancer biology, redox regulation, and oxidative stress signaling. Its selectivity for RAS/BRAF-mutant tumor cells and robust mechanism—via VDAC modulation and system Xc⁻ inhibition—enable precise modeling of iron-dependent, non-apoptotic cell death. Ongoing advances in sphingolipid metabolism, HIF-1 signaling, and ferroptosis inhibition (e.g., myriocin effects) are redefining the boundaries of Erastin’s research utility (Liu et al., 2022). As highlighted by APExBIO and independent studies, Erastin’s reproducibility and defined action profile provide a reliable foundation for translational ferroptosis research and therapeutic innovation.